Belluscura (LSE:BELL) OCF Margin %: -406.33% (As of Jun. 2024)


What is Belluscura OCF Margin %?

Belluscura LSE:BELL OCF Margin % is -406.33% as of Jun. 2024.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Belluscura's Cash Flow from Operations for the six months ended in Jun. 2024 was £-4.30 Mil. Belluscura's Revenue for the six months ended in Jun. 2024 was £1.06 Mil. Therefore, Belluscura's OCF Margin % for the quarter that ended in Jun. 2024 was -406.33%.

As of today, Belluscura's current OCF Yield % is 0.00%.

The historical rank and industry rank for Belluscura's OCF Margin % or its related term are showing as below:

LSE:BELL' s OCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -538.35

LSE:BELL's OCF Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 5.86 vs LSE:BELL: -538.35

Belluscura OCF Margin % Related Terms

Belluscura OCF Margin % Historical Data

* Premium members only.

The historical data trend for Belluscura's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belluscura OCF Margin % Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
OCF Margin %
Get a 7-Day Free Trial -780.61 0.00 -1,662.66 -1,066.03 -1,106.44

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1,646.05 -677.70 -1,335.52 -923.14 -406.33

LSE:BELL vs ABT, BSX, SYK: OCF Margin % Comparison

For the Medical Devices subindustry, Belluscura's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belluscura OCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Belluscura's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Belluscura's OCF Margin % falls into.


Belluscura OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Belluscura's OCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-7.214/0.652
=-1,106.44 %

Belluscura's OCF Margin for the quarter that ended in Jun. 2024 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-4.299/1.058
=-406.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -406.33% mean?
Belluscura (LSE:BELL) has a OCF Margin % of -406.33% as of Jun. 2024. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Belluscura and its competitors.
Is Belluscura's OCF Margin % too high?
Belluscura's current OCF Margin % is -406.33%.
How does Belluscura's OCF Margin % compare to ABT and BSX?
Belluscura's OCF Margin % of -406.33% can be compared against companies in the Medical Devices & Instruments industry. The industry median OCF Margin % is 5.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Belluscura and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Belluscura's current OCF Margin % is -406.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belluscura stock overvalued right now?
Belluscura (LSE:BELL) has a current OCF Margin % of -406.33%. The current OCF Margin % is -406.33%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Belluscura (LSE:BELL), the current OCF Margin % is -406.33% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belluscura Business Description

Address 15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.